SCHEMBL6690765

SCHEMBL6690765

O=[N+]([O-])c1ccc(Cl)c(-c2cscc2NS(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NHERF1 O14745 1/20 0.45
MCL1 Q07820 1/20 0.45
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
FSCN1 Q16658 1/20 0.41
SLC40A1 Q9NP59 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
KDM1A O60341 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MAOA P21397 1/20 0.38
FLT1 P17948 2/20 0.37
FLT4 P35916 2/20 0.37
KDR P35968 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6611870 0.93 NHERF1 (0.48) NHERF1MCL1CRHBPCRHR2FSCN1
SCHEMBL6610921 0.81 CRHBP (0.58) CRHBPCRHR2TDP1KDM1AMEN1
SCHEMBL6611561 0.81 NHERF1 (0.44) NHERF1MCL1CRHBPCRHR2FSCN1
SCHEMBL2762529 0.80 KDM1A (0.57) FSCN1KDM1AMEN1KMT2AMAPT
SCHEMBL6611905 0.80 NHERF1 (0.48) NHERF1MCL1CRHBPCRHR2FSCN1
SCHEMBL6694171 0.79 SLC40A1 (0.48) MCL1SLC40A1TDP1KDM1AMEN1
SCHEMBL6614021 0.79 CRHBP (0.47) NHERF1MCL1CRHBPCRHR2TDP1
SCHEMBL5831263 0.79 FSCN1 (0.47) NHERF1MCL1FSCN1TDP1KDM1A
SCHEMBL5830398 0.78 MEN1 (0.47) NHERF1MCL1CRHBPCRHR2FSCN1
SCHEMBL6613132 0.75 MCL1 (0.47) NHERF1MCL1CRHBPCRHR2FSCN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 NHERF1 889/4885MCL1 3245/4885CRHBP 2024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.